Skip to main content
Premium Trial:

Request an Annual Quote

Enzo Biochem Q3 Revenues Nearly Double on Clinical Lab Testing Demand

NEW YORK – Enzo Biochem reported after the close of the market on Wednesday that its fiscal year 2021 third quarter revenues rose 94 percent year over year, driven by a surge in its Clinical Lab revenues.

For the three months ended April 30, the diagnostics company reported total revenues of $32.8 million compared to $16.9 million in the year-ago quarter.

Its Q3 Clinical Lab revenues climbed to $25.0 million, up 138 percent year over year from $10.5 million, reflecting heightened testing activity, and its Life Sciences revenues grew to $7.8 million, up 22 percent year over year compared to $6.4 million.

Enzo Biochem "delivered another solid quarter … with significant profitability during an extraordinary period of transformation for the lab testing market," Elazar Rabbani, the firm's chairman and CEO, said in a statement. As COVID-19 testing volumes normalize, "Enzo's fully integrated diagnostic approach will evolve to address broader market needs," he said.

The recent quarter reflected growing demand for testing services and a steady improvement in sales of its products and services, the firm said.

Enzo noted that among its Q3 business highlights, it received US Food and Drug Administration Emergency Use Authorization for its Ampicollect Sample Collection kit.

The company's go-forward commercial strategy involves leveraging its higher-margin testing model demonstrated during COVID-19 to other markets such as women’s health, sexually transmitted diseases, and other applications for its Genflex molecular platform. The platform is in the early stage of commercialization, the firm said, adding that it intends to target it toward laboratories, academic institutions, and other commercial entities throughout the US.

The company reported net income of $2.0 million, or $.04 per share, compared to a net loss of $9.9 million, or $.21 per share, a year earlier.

Enzo's Q3 R&D expenses fell 27 percent to $800,000 from $1.1 million a year ago, while its SG&A expenses rose 9 percent to $12.1 million from $11.1 million in the prior-year quarter.

At the end of the quarter, Enzo had cash, cash equivalents, and marketable securities of $45.0 million.

The company said it expects to see COVID-19 testing volumes decline in the quarters ahead.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.